cisplatin + vandetanib + vinorelbine

This is a combination regimen consisting of three drugs: cisplatin, vandetanib, and vinorelbine. Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. Vandetanib is an oral small molecule inhibitor targeting vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR), and RET tyrosine kinase, thereby inhibiting tumor angiogenesis and cell proliferation. Vinorelbine is a third-generation vinca alkaloid that disrupts microtubule formation during mitosis, leading to cell cycle arrest and apoptosis. This combination has been investigated as first-line therapy for advanced non-small cell lung cancer (NSCLC) in clinical trials[2][4]. The rationale for combining these agents lies in their complementary mechanisms of action—targeting DNA integrity, angiogenesis/growth signaling pathways, and mitotic spindle assembly—to enhance antitumor efficacy.